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Role of the Ang-Tie2 pathway in the invasive recurrence of GBM following antiVEGF therapy
by
Nahir Cortés Santiago
Supervisory Professor: Candelaria Gómez-Manzano, M.D.

Strong pre-clinical and clinical data supporting the effectiveness of bevacizumab,
a humanized monoclonal anti-VEGF antibody, for the treatment of gliomas led to its
accelerated approval for the treatment of patients with recurrent glioma.

However,

despite strong anti-tumor effects, upon treatment with bevacizumab, patients will
invariably recur with a tumor characterized by enhanced invasiveness and resistance to
therapy.

This study aims to elucidate the mechanisms leading to this enhanced

malignancy with the hope of uncovering new potential therapeutic targets for combined
treatment. Using tissue sections from U87-derived glioma bearing mice treated with or
without aflibercept (another anti-VEGF antibody) we have gathered evidence of a
significant increase in the number of Tie2 expressing monocytes (TEMs) within the
tumor after treatment, particularly around areas of invasion. TEMs are a pro-angiogenic
subset of circulating monocytes that express the Tie2 receptor. Our data demonstrates
that TEMs have higher expression and activity of pro-invasive molecules, such as MMP2
and MMP9, than their Tie2 negative counterparts and are able to increase glioma cell
invasion in vitro, suggesting an active role of these cells in the invasive process observed
after treatment. Furthermore, we have shown that expression of angiopoietin 2 (Ang2), a
Tie2 ligand, is dramatically increased in the periphery of the tumor after aflibercept
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treatment. Interestingly, our data provides evidence that Ang2 is chemoattractant to
TEMs, both in vitro and in vivo suggesting a potential mechanism of recruitment of these
cells to the tumor. These data suggests an active role of the Ang-Tie2 pathway, and in
particular Ang2, in the invasive recurrence of GBM following anti-VEGF therapy and
that targeting it in combination with anti-VEGF therapy could lead to improved
outcomes. Supporting this idea, we were able to observe a dramatic decrease in the
invasive phenotype after anti-VEGF treatment when we inhibited the Ang-Tie2 pathway
in combination with an anti-VEGFR antibody. These results have important implications
for patients with GBM since a decrease in the invasive pattern upon recurrence after antiangiogenesis therapy could potentially render the tumors amenable to surgical excision
upon recurrence. This in turn can lead to improved patient survival.
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Chapter I: Background information and significance

I.

Glioblastoma
Glioblastoma (GB) is the most common and aggressive (grade IV) primary brain

malignancy in adults. Despite therapeutic advances within the last ten years, patients
diagnosed with GB have a grim prognosis with median survival ranging between15-18
months and a 5 year survival rate of less than 5%.1-2

Even with aggressive therapy with

the standard of care, which consists of maximal surgical resection coupled with
radiotherapy and chemotherapy with temozolomide, GB patients inevitably present with
recurrent disease.3
Pathologically, it is characterized by extensive necrosis and microvascular
proliferation, which makes them highly vascular tumors.2 One of the most important
mechanisms through which these tumors acquire such prominent vascularity is through
activation of hypoxia inducible factor (HIF) which drives the expression of vascular
endothelial growth factor (VEGF).4 Along this line, bevacizumab, an anti-VEGF
antibody, was recently granted accelerated approval by the FDA for the treatment of
recurrent GB due to unprecedented results in clinical trials.5-6

II.

Angiogenesis
The generation of stable, functional blood vessels and vascular networks is an

essential biological process, without which complex organisms such as ourselves could
not exist.

To date, two main processes through which this can occur have been

described: vasculogenesis, which is the process of de novo vessel formation from
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endothelial precursors, and angiogenesis, which is the formation of new blood vessels
from pre-existing ones.7 Vasculogenesis mainly occurs during embryogenesis, in which a
primitive vascular network is established from endothelial precursor cells named
angioblasts.7 Following this initial step, angiogenesis takes over and allows for the
ramification of this primitive vascular network and establishment of complex vascular
networks that deliver nutrients and oxygen throughout the human body.7 In healthy
adults, most vasculature is quiescent, and angiogenic processes are circumscribed to
organ systems in which vascular remodeling is essential for its function (i.e. female
reproductive tract) or for the purposes of wound healing.8

However, pathological

angiogenesis has been described for several disease processes (i.e. inflammatory disease
states, cancer) and the role of active angiogenesis in tumor development has been
extensively studied (see below).8

The VEGF-VEGFR pathway in angiogenesis
The establishment of new functional blood vessels is a complex multistep process.
Physiological stimuli, such as hypoxia, initiate this process mainly through upregulation
of vascular endothelial growth factor (VEGF).

VEGF, was initially described and

purified as a tumor secreted factor capable of inducing vascular permeability and was
therefore named vascular permeability factor (VPF).9 Several years after, Leung et al.
independently reported the discovery of vascular endothelial growth factor, a potent
endothelial cell mitogen capable of inducing angiogenesis.10 VPF and VEGF were
described to be the same molecule by Keck et al. shortly after the discovery of VEGF.11
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The VEGF family is composed of five ligands, namely VEGF-A (from now on
referred to as VEGF), VEGF-B, VEGF-C, VEGF-D and placental growth factor. VEGFA mRNA can be alternatively spliced to produce four main different isoforms: VEGF121,
VEGF165, VEGF189 and VEGF206.12-13 Three tyrosine kinase receptors have been
described so far, namely VEGFR1, VEGFR2 and VEGFR3 with other co-receptors
described such as neuropilins. Evidence gathered so far demonstrate that VEGFR2 is the
most important mediator of endothelial cell responses to VEGF and therefore therapeutic
approaches aimed at targeting the receptor are directed against VEGFR2.14-15
As described above, VEGF is a potent mitogen and pro-survival molecule for
endothelial cells. Its expression is upregulated by environmental stimuli such as hypoxia
and upon binding to VEGFR leads to endothelial cell proliferation and migration, two
key events without which angiogenesis cannot occur.8 Hypoxia also leads to increased
matrix metalloproteinase (MMP) expression, such as MMP9, which degrade the
extracellular matrix (ECM) around the cell. This has a dual effect: releasing VEGF
bound to ECM making it available for interaction with its receptor and degrading the
ECM providing a path for endothelial cell migration.8 In parallel to VEGF upregulation,
loosening of pericyte/endothelial cell interactions occurs mainly through the activity of
angiopoietin 2 (Ang2), a Tie2 ligand (see below). This “uncovers” endothelial cells
causing them to become more sensitive to VEGF. In the presence of high VEGF levels,
endothelial cells begin to proliferate and migrate forming a cell column that eventually
fuses forming a lumen through which blood can flow.

Elongation of this tubular

structure occurs through endothelial cell proliferation and migration in response to a
VEGF gradient and continues to occur as long as the pro-angiogenic stimuli are present.
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Eventually, pericyte cells are recruited, and pericyte/endothelial cell interactions are
established leading to the formation of a functional new vessel.16 The Ang-Tie2 pathway
plays an essential role in this process (see below).

The Ang-Tie2 pathway
The Ang-Tie2 pathway is extremely important for normal blood vessel
physiology. It is composed of two type I tyrosine kinase receptors, namely Tie1 and
Tie2. Tie2 was initially described by Dumont et al. as an endothelial cell specific orphan
receptor.17 This changed in the following years, with the discovery of its currently known
ligands, the angiopoietins (Ang).18-20 The importance of the Tie2 receptor in the vascular
system was highlighted by loss of function studies that showed that lack of Tie2 led to
embryonic lethality at E10.5 to E12.5. These mice were unable to form a vascular
network beyond the primary capillary plexus. These early vessels failed to mature and
showed fewer endothelial cells and diminished branching, as well as decreased pericyte
and smooth muscle cell coverage.21-22 Consistently, gain of function studies in which
Ang1, the main Tie2 agonist (see below), led to opposite changes. Overexpression of
Ang1 in skin led to numerous blood vessels that were highly branched, with decreased
intrinsic, or induced, leakiness due to enhanced supporting cell coverage (pericytes and
smooth muscle cells).23-24
The ligands of the Tie2 receptor are referred to as angiopoietins. There are three
human angiopoietins (Ang), namely Ang1, Ang2 and Ang4 (Ang3 is an Ang4 mouse
ortholog).18-20 Ang1 and Ang2 are the most widely studied human Tie2 ligands. Ang1 is
considered to be the main Tie2 agonist and as such, loss of function studies led to similar
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outcomes as knockdown of Tie2.25 Upon binding to Tie2, it leads to dimerization or
multimerization, and auto-phosphorylation of tyrosine residues located in the intracellular
domain of the receptor. This leads to binding and activation of downstream targets
ultimately leading to endothelial cell survival and vessel stability.26 Tie2 and Ang1 are
widely expressed in the adult vasculature and are required for the maintenance of a
functional quiescent vascular network.8
Ang2 is considered to be a natural Ang1 antagonist. This notion came from gain
of function studies in which mice engineered to overexpress Ang2 had similar vascular
defects as mice deficient for Ang1.19 Further evidence of its antagonistic functions came
later when mice with conditional overexpression of Ang2 were shown to be unable to
phosphorylate Tie2, the idea being that when Ang2 is present it binds to the Tie2 receptor
effectively preventing binding of Ang1.27 This in turn leads to loosening of pericyte
coverage and vessel destabilization.

The end result of Ang2 activity on vascular

structures will largely depend on the presence or absence of VEGF. Loosening of
pericyte coverage sensitizes endothelial cells to the effects of VEGF, and therefore, in the
context of high VEGF expression, Ang2 potentiates its effects and functions as a proangiogenic molecule leading to enhanced endothelial cell migration and sprouting. On
the other hand, in the absence of the pro-survival and mitogenic stimuli conferred by
VEGF, lack of pericyte coverage causes endothelial cells to undergo apoptotic cell death.
In this context, high Ang2 expression leads to vessel regression.28 Interestingly, the role
of Ang2 in the Ang-Tie2 pathway has proven to be complex and in the absence of Ang1,
Ang2 has been shown to partially activate the Tie2 receptor.29 Furthermore, Ang1 has
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been shown to reverse the effects of Ang2 inhibition in colon, prostate and epidermoid
carcinomas, suggesting Ang2 can function as a Tie2 agonist under certain conditions.30
There are other roles of the Ang-Tie2 pathway outside blood vessel physiology
and pathology.

For example, loss-of-function studies have shed light into other

physiological roles for Ang2. Although normal embryonic development is not hampered
by lack of Ang2, mice with knocked down Ang2 expression develop chylous ascites that
is lethal in the 129/J genetic background.31 This result suggests an important agonistic
role of Ang2 in the development of lymphatic vasculature. Furthermore, mice deficient
for Ang2 are incapable of mounting a rapid inflammatory reaction in response to TNF-α,
suggesting a key role for this cytokine in inflammation. In depth studies on how Ang2 is
capable of regulating the inflammatory response have shown that late stages of leukocyte
recruitment, which involve firm adhesion and transmigration are affected by the absence
of Ang2, whereas initial stages, namely chemoattraction and selectin-mediated rolling
and tethering, are not affected.32 The Ang-Tie2 system has also been shown to be crucial
for the maintenance of the hematopoeitc stem cell (HSC) niche. HSC expressing the
Tie2 receptor were found to be a side population within the bone marrow with a
quiescent phenotype and anti-apoptotic features. Osteoblasts and stromal cells within the
bone marrow produce Ang1 that binds to and activates Tie2 within HSC in a paracrine
manner. This constitutive activation of the Ang-Tie2 pathway has been shown to be
essential for maintenance and repopulation of the stem cell niche within the bone
marrow.33 Finally, Ang1 has neuro-protective effects through inhibition of apoptotic cell
death in neurons. Whether the latter is mediated by Tie2 still needs to be clarified.34
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Angiogenesis in cancer
Angiogenesis is a highly complex process requiring a tightly regulated interplay
of many molecular pathways, both pro- and anti-angiogenic. An imbalance towards
either one of the extremes of the spectra can lead to dysfunctional vasculogenesis and
angiogenesis. For example, genetic knockdown of even one VEGF allele leads to early
embryonic death due to abnormal vasculature formation.35 On the other hand, a proangiogenic environment lacking appropriate regulation can lead to disease, cancer being
an example of the latter.8 The effective generation of a vascular network is considered to
be a rate-limiting step in tumor progression. The growth of any solid mass beyond a few
millimeters requires the concomitant formation of blood vessels that allow oxygen and
nutrient delivery to tumor cells, as well as waste removal from the tumor bed.36
Tumor progression has historically been described in two major phases, namely
avascular and vascular. The avascular phase of tumor growth is characterized by the
acquisition and accumulation of genetic alterations that confer a given cell a proliferative
and survival advantage. This leads to uncontrolled cell proliferation and the resulting
formation of a small lesion. Eventually, the lack of blood supply to central areas of the
tumor hampers expansion and the mass reaches a point where apoptosis equals cell
proliferation and no further growth occurs.37-38 In the absence of angiogenesis, these
lesions can remain dormant for years and cause no disease. Underlining the importance
of vascular formation to generate a clinically significant tumoral lesion, there have been
reports of accidental findings of small, occult lesions in autopsies from patients that died
from a different cause.39 This supports the idea that only a subset of tumors eventually
enters the second, vascular phase in which exponential tumor growth occurs. Although
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extensive research on the subject has shed some light into the mechanisms underlying
this “angiogenic switch”, the subject remains obscure.
Angiogenesis is the main mechanism through which tumors acquire a vascular
network.

However, some solid tumors have been shown to induce de novo vessel

formation through the recruitment of endothelial precursor cells from the bone marrow, a
process called vasculogenesis.40 Adding to the complexity of tumor vascularity, cancer
cells have been shown to integrate in the vessel wall.41 Similar to physiologic
angiogenesis, initiation of tumor angiogenesis can be triggered by the sole overexpression
of VEGF. However, the imbalance of pro- and anti-angiogenic stimuli within the tumor
microenvironment leads to the formation of chaotic vascular networks, with deregulated
maturation and diminished or absent pericyte coverage.42 This leads to vessels containing
features of capillaries, venules and arterioles altogether. Lack of pericyte coverage leads
to enhanced sensitivity to VEGF stimulation, which generates a vicious cycle of ongoing
angiogenesis and the production of dilated leaky vessels that differ in great extent to their
normal counterparts.

III.

Anti-angiogenesis therapy: development and challenges
The idea that targeting angiogenesis for cancer treatment could be useful was first

proposed by Judah Folkman in 1971.43 The discovery of VEGF and the understanding of
its essential role in angiogenesis provided the basis for the development of several types
of inhibitors of this pathway to target angiogenesis. Antibodies against VEGF and its
receptor (VEGFR), tyrosine kinase inhibitors with selectivity towards VEGFR and
soluble VEGFR formulations have been developed, and in some cases FDA approved, for
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the treatment of disease, including cancer. The idea behind these efforts being that
without an active VEGF pathway, angiogenesis cannot occur and tumors would “starve”
to death.
Bevacizumab, one of the currently FDA approved anti-angiogenesis agents, is a
humanized monoclonal antibody that binds vascular endothelial growth factor and traps it
in the circulation preventing it from interacting with the VEGF receptor (VEGFR). Its
precursor, a murine monoclonal antibody (muMAb 4.6.1) was developed by Kim et al. in
an attempt to better understand the physiological roles of VEGF shortly after its
discovery.44 It was shown to bind and effectively inhibit VEGF-mediated endothelial cell
proliferation and vascular permeability. A year later, the same group published a study
demonstrating that VEGF induced angiogenesis in vivo and that targeting VEGF in vivo
with mAB 4.6.1 led to decreased vessel density and inhibition of tumor growth in three
tumor models: leiomyosarcoma, GBM and rhabdomyosarcoma.45 This was the first study
to demonstrate that targeting VEGF in vivo led to decreased angiogenesis and tumor
growth inhibition, establishing a precedent for further drug development. Even though
the biggest attention was given to the potential of targeting VEGF in cancer, this strategy
was also investigated in other models of disease. For example, diabetic retinopathy is
characterized by hypervascularization of the retina, and studies were able to show that
targeting VEGF in this context led to diminished vessel density in models of this
disease.46 Furthermore, rheumatoid arthritis also has a prominent vascular component and
some studies suggested that inhibiting VEGF in this context could be useful.47
In 1997, five years after its development, Presta et al. published the humanization
of mAb 4.6.1, now named bevacizumab.48 Bevacizumab had similar binding affinities to
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VEGF, as well as tumor growth inhibitory properties as those observed for mAb 4.6.1.
With this, a tool for testing the effectiveness of targeting VEGF in human disease was
established. The first placebo controlled trial was published by Yang et al.49 Patients with
metastatic renal carcinoma were given placebo, low-dose bevacizumab or high dose
bevacizumab. Primary end points were time to progression of disease and response rate,
with overall survival being a secondary endpoint. Results demonstrated a significant
increase in progression free survival, particularly in the high-dose bevacizumab group
when compared with placebo. No change in overall survival was observed. Since then,
many clinical trials have been conducted in several types of solid tumors leading to the
approval of bevacizumab for the treatment of non-small cell lung carcinoma, metastatic
colorectal and renal cell carcinoma and, of particular interest to us, second line treatment
for GBM.
The first report on the use of bevacizumab in GBM was done by Stark-Vance and
was presented as an abstract at the 2005 European Association of Neuro-Oncology.50 She
treated 11 patients who had recurrent GBM with 5mg/kg of bevacizumab combined with
125mg/m2 irinotecan (CPT-11) and was able to show anti-tumor activity. This opened
the door for clinical trials with bevacizumab for the treatment of recurrent GBM.
Historically, patients treated with conventional therapy had radiographic responses of 9%
and 6-month progression free survival ranging between 9-15%. Clinical trials performed
with bevacizumab demonstrated an improvement of both these measures, producing
radiographic responses ranging between 24-57% and 6-month PFS of 25-65%.
Furthermore, its vascular normalization effects led to decreased cerebral edema and
intracranial pressure, which resulted in a decrease in corticosteroid use in these patients
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and a consequent improvement in quality of life.51 The FDA granted accelerated approval
of bevacizumab in 2009 for the treatment of recurrent GBM due to the outcomes reported
on clinical trials5-6 and it is currently standard of care for this patient population. Data on
overall survival (OS), the most important parameter used to evaluate therapeutic efficacy,
is not available for recurrent GBM. However, two recent phase III clinical trials in which
the efficacy of bevacizumab as a first line agent for GBM was evaluated concluded that
bevacizumab did not lead to increased OS when compared to conventional therapy.52-53
Whether this translates to the setting of recurrent GBM is undetermined since no largescale clinical trial with OS as a primary endpoint has been done for bevacizumab in this
context. Importantly, progression free survival was improved in both studies, although
the pre-specified improvement target was not achieved in one of them.53
Even though bevacizumab led to an improvement in quality of life, progression
free survival and radiographic responses in GBM, the idea of it being a miracle drug is
far from reality.

Despite its benefits, patients treated with bevacizumab invariably

present with recurrent disease and upon recurrence, the tumors acquire a highly invasive
phenotype that is resistant to all currently available therapies. At this point, prognosis is
measured in short weeks. The notion that bevacizumab treatment leads to enhanced
invasion in gliomas dates to the year 2000, way before it was tested in the clinic and
many years before its approval for the treatment of recurrent GBM. Rubenstein et al.
reported the use of bevacizumab for the treatment of intracranial glioma for the first time
in an animal model.54 They demonstrated the effectiveness of bevacizumab at increasing
survival, decreasing vessel density and increasing apoptosis of intracranial glioma, and
discuss the infiltrative behavior of the tumor upon recurrence as an adaptation to anti-
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angiogenic therapy. Since then, concerns regarding this highly aggressive and infiltrative
behavior after anti-VEGF therapy has been raised in several studies, both in animal
models as well as in patients.55-56 Evidence gathered demonstrated that targeting either
VEGF or VEGFR led to similar outcomes, suggesting that this phenomena was a result of
targeting the pathway, and did not necessarily stem from the approach taken to do so
(targeting VEGF or VEGFR). In 2009, Paez-Ribes et al. established the unequivocal link
between inhibiting VEGF and highly aggressive and infiltrative behavior.55 In their study,
they demonstrated that both, pharmacological inhibition of the VEGF pathway as well as
genetic knockdown of VEGF, led to tumor progression with increased vessel cooption
and enhanced invasion in a GBM model and pancreatic neuroendocrine carcinoma
model, the latter having higher rates of distant metastasis in the context of VEGF
inhibition. Understanding how the tumors acquire this invasive and resistant phenotype
following anti-VEGF therapy will be essential for improving GBM treatment and
outcomes.

IV.

The tumor microenvironment
Historically, research on cancer has focused on understanding the events

occurring within tumor cells for tumorigenesis to take place. Intensive efforts led to the
identification of mutational events required for an epithelial cell to be transformed and
become tumorigenic. A prime example of such efforts is the characterization of the
genetic alterations that occur in the progression from benign epithelial hyperplasia to
invasive carcinoma in colon cancer. However, tumors are not composed of an isolated
mass of transformed epithelial cells, but of a composite of extracellular matrix, blood
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vessels and immune cells, among other stromal components. These components outside
of the epithelial compartment are known as the tumor microenvironment.57 It is now
widely accepted that communication and interactions between transformed epithelial
cells and its microenvironment are essential for development, progression and therapeutic
response of any neoplastic growth, and that components within this microenvironment
can be exploited therapeutically.58 Immune cells are one of the most widely represented
cells in the tumor microenvironment, and within this group, cells of the myeloid lineage,
particularly monocyte/macrophages (tumor associated macrophages – TAMs), are of the
most abundant.

Monocytes and macrophages
Macrophages are characterized by their remarkable plasticity. Depending on the
micro-environmental needs, their functions can range from immune activation and
pathogen recognition and clearance to scavenging, immune suppression and wound
healing. This wide variety of, and sometimes opposing, functions underline the ability of
macrophages to sense cues from the microenvironment and adapt to these so that
appropriate immunological responses can be mounted.

In this way, macrophages

function as switches of the immune system and can develop into different subsets to tailor
and regulate immune responses.59
The most widely accepted model of macrophage differentiation is the M1-M2
polarization spectrum.

In one end, M1 macrophages are considered to be pro-

inflammatory monocytes that activate the immune system via inflammatory cytokine
production and antigen presentation.

This subset of macrophages is activated by
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microbial products such as lipopolysaccharide (LPS) and pro-inflammatory molecules
such as IFNγ and they aid in the process of pathogen recognition and clearance.59 On the
other end, M2 macrophages are activated by IL4 and IL13 and they function to keep the
immune system in check by producing large amounts of anti-inflammatory molecules
that regulate and terminate inflammatory reactions initiated by M1 polarized
macrophages.

Furthermore, M2 polarized macrophages have scavenging and pro-

angiogenic properties that are important in the normal process of wound healing.60-61 At
any given moment, macrophages exist somewhere in the middle of this spectrum with
environmental signals tilting the pro- and anti-inflammatory balance to one side or the
other.
Although macrophages can potentially have anti-tumor effects, the bulk of the
evidence available so far suggests that tumor associated macrophages (TAMs) enhance
tumor survival and hamper response to therapy in a wide variety of solid tumors,
including breast carcinoma, prostate carcinoma, bladder carcinoma and gliomas.62-67 In
gliomas, monocyte/macrophages are one of the most widely represented cells within the
tumor microenvironment.68 Studies aimed at understanding the characteristics of these
cells within gliomas have shown that the bulk of these tumor-associated macrophages are
M2-polarized, a profile consistent with a pro-tumorigenic phenotype.69 The mechanisms
through which these cells can promote tumor progression are varied and include
diminished anti-tumor activity, immune suppression and the production of cytokines and
chemokines that induce glioma cell proliferation, angiogenesis and invasion.
Furthermore, glioma cells are capabable of producing soluble mediators that perpetuate
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this pro-tumorigenic phenotype in macrophages establishing this way a vicious cycle
leading to enhanced malignancy.70

Tie2 expressing monocytes
As the name implies, Tie2 expressing monocytes (TEMs) are a subpopulation of
circulating monocytes expressing the Tie2 receptor. They were discovered in 2005 by De
Palma et. al. as an effort to characterize the Tie2 expressing cell population within
tumors.71 Through the use of a transgenic mouse model in which GFP expression was
driven by transcriptional regulatory elements present within the Tie2 gene [TgN(Tie2GFP)], they identified a population of Tie2 expressing cells within the stromal
compartment of N202 mammary tumors that co-express the monocytic marker CD11b,
i.e Tie2 expressing monocytes. Co-injection experiments in which nude mice were
implanted with N202 mammary carcinoma cells in conjunction with TEMs isolated from
TgN(Tie2-GFP) mice, demonstrated that TEMs have remarkable pro-angiogenic
properties, with tumors co-injected with TEMs having a 4-fold higher average vascular
area than controls. As a continuation of this work, in 2007 Venneri et al. described the
presence of TEMs in peripheral blood of healthy donors, as well as in human tumor
samples, establishing a link between the findings in the mouse mammary tumor model
and human disease.72 Tie2 expressing monocytes have also been studied in the context of
hepatocellular carcinoma.

Matsubara et al. showed that TEMs increase in patients

suffering from HCC and that their numbers correlate with response to therapy, i.e.
surgery, as well as tumor recurrence.73 Given these data, the authors highlight the

15

potential of using TEMs as biomarker for HCC. Finally, their selective recruitment to
tumors has been exploited as a tool for drug delivery.74
Due to their relatively recent discovery, reports on TEMs and their biological
properties are still limited. The bulk of the research performed so far has been directed to
further elucidate their role in tumor angiogenesis and progression. In 2009, Pucci et al.
analyzed the gene signature of TEMs in comparison to TAMs, endothelial cells and other
myeloid derived cells, such as neutrophils.75 Their work further confirmed that TEMs are
part of the myeloid lineage, since they posses higher expression of myeloid genes such as
csf1, Fc receptors and cd14, while having negligible amounts of endothelial derived
genes. Their expression profile is also consistent with their pro-angiogenic role, having
higher expression of mRNAs classically associated with angiogenesis, such as vegfa,
vegfb, and pdgf. Furthermore, expression of M2 polarization markers such as arginase
and mannose receptor placed TEMs in this end of the monocyte/macrophage polarization
spectra, further supporting their pro-tumorigenic properties.69,

75

The role of the Tie2

receptor in this monocyte subpopulation is still unclear. However, the Tie2 ligand Ang2,
has been shown to promote their pro-angiogenic and pro-tumorigenic properties. In their
work published in 2009, Coffelt et al. provided evidence that Ang2 can recruit TEMs to
tumors and enhance their pro-angiogenic properties.76 In their follow up work, they
extended the role of TEMs to that of an immunomodulatory cell capable of inducing an
immune suppressed microenvironment through the expression of IL10. Interestingly,
Ang2 was capable of further enhancing their expression of this cytokine, which then led
to suppression of T cell proliferation, increase in the CD4+/CD8+ T cell ratio and
expansion of Tregs.77 Therefore, although literature on TEMs is still limited, the bulk of
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the evidence heavily supports the notion that this cell population support tumor
progression and their presence could be associated with worse patient prognosis

Glioblastoma multiforme is one of the deadliest malignancies known to man.
Extensive research efforts have only led to modest advances in therapy and patient
outcomes. The purpose of this investigation is to better understand the events leading to
recurrence following anti-VEGF therapy (i.e. bevacizumab) in GBM with the ultimate
goal of identifying new therapeutic targets for combined treatment.

Based on the

available evidence, we hypothesize that the Ang-Tie2 pathway plays a key role in the
recurrence of GBM after anti-angiogenesis treatment. A corollary of this hypothesis
being that targeting this pathway in combination with anti-VEGF therapy could lead to
improved outcomes in GBM.
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Chapter II: Materials and Methods

Cell Culture. U87 malignant glioma and THP-1 monocytic leukemia cell lines were
obtained from the American Type Culture Collection. GSC20 glioma stem cells were
established from a human glioblastoma surgical specimen at MD Anderson Cancer
Center (Houston, TX). GL261 mouse glioma cells were obtained through the NCIFrederick Cancer Research Tumor Repository (Frederick, MD).

GL261.GFP and

GL261.sTie2 established cell lines were a kind gift from Luc Vallières (Quèbec, CA),
Ph.D. U87 MG cells were cultured in Minimum Essential Medium Eagle (MEM) with
10% FBS and 1% essential amino acids under the same conditions. THP-1 monocytic
leukemia cell line was cultured in RPMI1640 media supplemented with 2mM Lglutamine and 10% FBS. GSC20 glioma stem cells were cultured using Dulbecco’s
Modified Eagle Medium/F12 supplemented with 1X B27 and 20ng/mL bFGF and
20ng/ml EGF. GL261, GL261.GFP and GL261.sTie2 cell lines were cultured in
Dulbecco’s Modified Eagle Medium/F12 supplemented with 10% FBS. All media was
supplemented with 100µg/ml penicillin and 100µg/ml streptomycin.

Immunohistochemistry. Five µm sections were deparaffinized in three washes of xylene
for 5 minutes each, followed by rehydration in serial dilutions of ethanol as follows:
100% ethanol twice for 5 minutes, 95% ethanol twice for 5 minutes and 70% ethanol
once for 5 minutes. Following a brief wash in PBS, endogenous peroxidase activity was
quenched using 3% H2O2 in 100% methanol for 10 minutes at room temperature. Heatinduced antigen retrieval was performed in a pre-warmed solution of 10mM citrate
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buffer, pH6 for 10 minutes in a pressure cooker. Slides were allowed to cool down at
room temperature for 30 minutes before washing and blocking using a 5% BSA in PBS
solution. Primary antibodies were diluted using IHC Tek diluent pH 7.4 (IHC World,
Cat. # IW1000) and placed at 4°C overnight. Biotin-conjugated secondary antibodies
(Vector Labs) were diluted 1:400 in IHC Tek diluent pH 7.4 and applied to tissue
sections for 1 hour at room temperature. This was followed by incubation with ABC
system (Vector labs, Cat. # PK4000) for one hour at room temperature.

3, 3’

diaminobenzidine (Sigma, Cat. # D4418) was used for signal detection.

Nuclei

counterstain was done using hematoxilin, after which slides were dehydrated in 100%
ethanol. Following a brief wash in xylene slides were mounted using CytoSeal (Thermo
Scientific, Cat. # 23-244257). Images were taken using a brightfield, Zeiss Axioskop 40
microscope at the designated magnification.

Immunofluorescence. Five µm sections were deparaffinized in three washes of xylene
for 5 minutes each, followed by rehydration in serial dilutions of ethanol as follows:
100% ethanol twice for 5 minutes, 95% ethanol twice for 5 minutes and 70% ethanol
once for 5 minutes. Blocking was done with a 5% BSA in PBS solution followed by
primary antibody diluted in IHC Tek diluent at 4°C overnight.

Biotin-conjugated

secondary antibodies were diluted 1:500 in IHC Tek diluent pH7.4 and placed on tissue
sections for one hour at room temperature. Dylight-conjugated streptavidin was used for
signal detection. When required, signal was amplified by an additional step of biotinconjugated anti-streptavidin antibody (Vector Labs, Cat. # BA0500, 1:1000) for 30
minutes at room temperature followed by an additional step of Dylight-conjugated
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streptavidin (Vector Labs, Cat. # SA-5488-1 and SA-5549-1, 1:1000) for 30 minutes at
room temperature. DAPI was applied for 15 minutes at room temperature for nuclear
counterstaining. Slides were then mounted using Dako Fluorescence Mounting Medium
(DAKO, Cat. # S3023). Images were taken in a fluorescent Zeiss Axiovert 200M
microscope at 20x magnification. For quantification purposes, at least eight pictures of
random fields were taken and manually quantified per slide.
Primary antibodies used for immunohistochemistry and immunofluorescence are
Ang2 (IHC World, ready-to-use), Ang1 (R&D, 1:100), VEGF (Santa Cruz, 1:500), Iba1
(Millipore, 1:1000), CD31 (R&D, 1:100), SMA (Dako, 1:100), hNuMA (abcam, 1:500),.
Secondary antibodies used are biotinylated anti-rabbit (Vector Labs), biotinylated antimouse (Vector Labs), biotinylated anti-goat (Vector Labs). Dylight-594 and Dylight-488
conjugated streptavidin (Vector Labs) was used for immunofluorescence detection.

M2 polarization and induction of Tie2 expression in THP-1 monocytic leukemia cell
line. THP-1 cells were placed in serum free media in the presence of 20ng/ml IL4 (R&D,
Cat. #204-IL-010) and 20ng/ml IL13 (R&D, Cat. #213-ILB-005) and placed in hypoxic
conditions (1% O2, 5% CO2 and 94% N2) for 48-72 hours. Tie2 expression was measured
via flow cytometric analysis following polarizing conditions.

Flow cytometric analysis. Cells of interest were harvested and washed three times with a
solution of PBS containing 0.5% BSA.

Incubation with primary antibodies was

performed at 4°C for 30 minutes in the dark, after which cells were washed twice with
PBS. Cells were resuspended in 500ul-2mL of PBS depending on total number of cells.
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Flow cytometry was done using a FacsCalibur flow cytometer from Beckton Dickinson
machine and expression was analyzed using CellQuest software.

In experiments

requiring sorting, expression was analyzed and sorting was performed using a
FACSAriaII cell sorter from Beckton Dickinson.
Primary antibodies used were phycoerythrin-conjugated mouse anti-human Tie2 (1:50,
R&D, Cat. #FAB3131P), fluorescein-isothyocyanate conjugated mouse anti-human
CD11b (1:50, Abcam, Cat. # ab25827-100), allophycocyanin conjugated mouse antihuman CD14 (1:50, R&D, Cat. #FAB3832A).

Isolation of monocytes from peripheral blood of healthy donors. Peripheral blood
mononuclear cells (PBMCs) were prepared from healthy donor blood (Gulf Coast
Regional Blood Center, Houston, TX) by centrifugation on a Ficoll-Paque Plus (GE
Healthcare, Cat. # 17-1440-02) density gradient at 950g for 20 minutes, with deceleration
set at zero. PBMCs were incubated in the presence of 20µl per 1x107 cells CD14
MicroBeads (Miltenyi Biotech, Cat. # 120-000-305) for 20 minutes at 4°C after which
cells were run through a magnetic column to isolate CD14 positive monocytes.
Monocyte-enriched population was then double stained with anti-human CD14-APC
(R&D Systems, Cat. # FAB3832A) and anti-human Tie2-PE (R&D Systems, Cat. #
FAB3131P). Stained cell suspension was then subjected to flow cytometric analysis and
cell sorting (FACSAria, Becton Dickinson) to obtain Tie2-negative (CD14+/Tie2-) and
Tie2-expressing monocytes (CD14+/Tie2+).
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Migration assays. For migration assays, THP-1 cells were placed in either normoxia or
hypoxia conditions in the presence or absence of 20ng/ml IL-4 and 20ng/ml IL-13 for 48
hours. In some experiments, cells were sorted according to Tie2 expression prior to
migration assay. For this purpose, cells were stained using phycoerythrin-conjugated
anti-Tie2 antibody (R&D, Cat. #FAB3131P) and subjected to flow cytometric analysis
and cell sorting using Becton Dickinson FACS Aria II.
24-well plates were used for migration assay with a transwell containing a 5µm
pore polycarbonate membrane (Corning, Cat. # 3422). Depending on the experiment,
1x105 treated or sorted THP-1 cells, were placed in a transwell, which was then placed
over a well containing 500µl of either 400ng/ml Ang2 (R&D, Cat. #623-AN-025) in
serum-free media or the equivalent amount of BSA. Cells were allowed to migrate for 24
hours, after which total number of migrated cells in the lower chamber was counted with
a hemocytometer using Trypan Blue. Results shown are the mean from three separate
migrations.

Invasion assays. For invasion assays, THP-1 cells were placed in normoxia or hypoxia
conditions in the presence or absence of 20ng/ml IL-4 and 20ng/ml IL-13 for 48 hours. In
some experiments, cells were stained using phycoerythrin conjugated anti-Tie2 antibody
(R&D, 1:50) and subjected to flowcytometric analysis and cell sorting using Becton
Dickinson FACS Aria II. Following sorting or polarizing conditions, cells were cultured
in RPMI media containing 1% fetal bovine serum for 24 hours. Conditioned media from
Tie2 negative and Tie2 positive cells were then collected and used for invasion assay.
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24-well plates were used for invasion assay with a transwell containing an 8µm
pore polycarbonate membrane (Corning, Cat. #3422).

Membrane was coated with

0.3mg/ml LDEV free, growth factor reduced matrigel matrix (BD Biosciences, Cat
#356230). Matrigel was allowed to solidify at room temperature for 2 hours prior to the
experiment. Depending on the experiment, 1x105 U87 glioma cells or GSC20 glioma
stem cells were seeded on the transwell, which was then placed over a well containing
500µl of conditioned media from either Tie2-negative or Tie2-positive monocytes. Cells
were allowed to invade for 24 hours, after which cells in the transwell were fixed and
stained using a solution of 0.1% crystal violet in 20% methanol at room temperature for
20 minutes. Non-invading cells within the upper portion of the transwell were removed
using a cotton swab and invading cells attached to the bottom side of the transwell were
quantified.

Gelatinase activity assay. Tie2 negative and Tie2 positive monocytes were obtained from
donor blood as described above. After sorting, cells were cultured in serum free media
for 24 hours after which conditioned media was used to detect gelatinase activity using
EnzCheck® Gelatinase/Collagenase Assay Kit (Life Technologies, Cat. #E12055) as per
manufacturer’s instructions. Briefly, conditioned media was incubated in the presence of
fluorescein-conjugated DQ-gelatin from pig skin at room temperature overnight in the
dark. Fluorescence was measured at 495nm.

Enzyme-linked immunosorbent assay. Tie2-positive and Tie2-negative monocytes were
isolated from peripheral blood as described above. After sorting, cells were cultured in
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serum free media for 24 hours after which conditioned media was collected. MMP2 and
MMP9 were detected using Quantikine ELISA Kit (R&D, Cat#MMP200 and DMP900)
as per manufacturer’s instructions. Briefly, conditioned media was diluted with Assay
Diluent provided and added to each well. After a 2 hour incubation at room temperature,
wells were washed and conjugated antibody against the protein of interest was added to
each well. After a 2 hour incubation period, wells were washed and a mixture of Color
Reagent A and Color Reagent B was added to the wells for at least 30 minutes. The
reaction was stopped using a sulfuric acid based solution and absorbance was read at
450nm.

BrdU incorportation assay. Cells were plated in a 96-well plate and allowed to attach
overnight. BrdU incporation assay was performed using BrdU Cell Proliferation Assay
Kit (Cell Signaling, Cat #6813) as per manufacturer’s instructions. Briefly, cells were
incubated at 37°C overnight in the presence of labeling agent. Media was aspirated and
cells were exposed to Fixing/Denaturing solution followed by incubation in detection
antibody solution at room temperature. Cells were then incubated in HRP-conjugated
secondary antibody followed by TMB substrate. Reaction was stopped after 30 minutes
using the provided Stop solution and absorbance was measured at 450nm.

In vivo experiments. All animal studies were performed in the Department of Veterinary
Medicine at The University of Texas MD Anderson Cancer Center (Houston, TX) in
accordance with institutional and ethical guidelines for experimental animal care and
approved by the MD Anderson IACUC.
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U87MG cells (5x105) were implanted intra-cranially in the caudate nucleus of
athymic mice as described before.

Briefly, a 2.6-mm guide screw with a 0.5-mm

diameter central hole is implanted into a drill hole made 2.5 mm lateral and 1 mm
anterior to the bregma. It is capped with a stylet between treatments. Tumor cells were
injected using a 26-gauge needle of a Hamilton syringe with a cuff to determine the depth
of injection. VEGF Trap was administered subcutaneously at 25mg/kg, twice a week
starting 10 days after implantation and continued for either 3 weeks or 6 weeks.
Bevacizumab treatment was administered intraperitoneally at 10mg/kg starting on day 5
post-implantation and continued for 6 weeks. Temozolomide treatment was administered
intraperitoneally at 7.5 mg/kg/day on days 4-8 and 11-22 post-implantation. Mice were
sacrificed when signs of high tumor burden were apparent.

Brains were extracted,

formalin fixed and paraffin embedded. Five µm sections were cut and mounted on slides
for histological and protein expression analysis.
GL261, GL261.Ctrl or GL261.sTie2 mouse glioma cells (2x105) were implanted
intracranially into the caudate nucleus of C57/BL6 mice as described above. DC101
treatment was administered intraperitoneally at 800µg/dose three times a week for a total
of 4 weeks. Mice were sacrificed when signs of high tumor burden were apparent.
Brains were extracted, formalin fixed and paraffin embedded. Five µm sections were cut
and mounted on slides for histological and protein expression analysis.

Statistical Analysis. The two-tailed Student t-test was used to determine the statistical
significance in in vitro experiments. Log-rank test was used to determine statistical
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significance of in vivo survival. Only p values less than 0.05 were accepted as statistically
significant.
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Chapter III: Tie2 expressing monocytes are recruited to the tumor following antiVEGF therapy

Rationale and expectations
In the process of angiogenesis, there is a tight interplay between the VEGF pathway and
the Ang-Tie2 pathway. This led us to hypothesize that in the context of anti-angiogenesis
therapy, the Ang-Tie2 pathway could be upregulated as a means to escape VEGF
blockade.

To test this, we initially evaluated the presence of Tie2 within tumors

following anti-VEGF therapy. We hypothesized that there would be an increase in Tie2
following anti-angiogenesis treatment.
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Results

Tie2-expressing cells accumulate in the periphery of the tumor after anti-VEGF
therapy. Tumor sections from glioma-bearing mice treated with either control hFc or
aflibercept were obtained and immunostaining for Tie2 was performed (Figure 1). We
tested two different VEGF-Trap/aflibercept schedules: a short 3-week schedule that did
not lead to an enhanced invasive pattern and a prolonged 6-week schedule that led to the
appearance of invasive nodules. As can be observed, there is a marked increase in the
number of Tie2-expressing cells in tumors treated with anti-VEGF therapy, particularly
in the periphery of the tumor and surrounding areas of invasion. Quantification of
positive cells shows this increase in Tie2-positive cells to be significant and
circumscribed to the periphery of the tumor. Interestingly, this significant increase in
Tie2 positive cells is only observed after prolonged (6-week) anti-VEGF therapy,
whereas 3-week treatment does not lead to an increase in these cells.
The morphological features of the Tie2 positive cells suggested they were not U87
glioma cells. They were characterized by small, rounded and normal appearing nuclei
with scant cytoplasm, which suggests they could be circulating immune cells infiltrating
the tumor or resident cells, such as microglia, proliferating from within the tumor.
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Tie2 expressing monocytes are recruited to the tumor following anti-VEGF therapy.
Monocytes/macrophages are one of the most abundant cells within the tumor
microenvironment in gliomas.68 Given the morphological features, we hypothesized that
these Tie2-expressing cells were in fact Tie2 expressing monocytes that are recruited to
the tumor following anti-VEGF therapy. To test our hypothesis, we obtained tissue
sections from glioma-bearing mice treated with VEGF-Trap/aflibercept for 3 or 6 weeks,
bevacizumab or temozolomide. Double staining for Iba1, a monocyte/microglia marker,
and Tie2 was performed and double positive cells were quantified. Our results confirmed
our hypothesis showing a marked and significant increase in the number of double
positive cells following anti-VEGF therapy with VEGF-Trap/aflibercept or bevacizumab.
TEMs were mainly localized around the tumor periphery and areas of invasion. Again,
this increase TEMs was only observed after a prolonged schedule of VEGFTrap/aflibercept when invasion occurs. Furthermore, treatment with temozolomide did
not lead to a similar outcome, providing evidence that TEMs are being selectively
recruited as a response to anti-angiogenic treatment.
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Conclusions

Tie2-expressing cells, and Tie2-expressing monocytes in particular, are selectively
recruited to the tumor following prolonged anti-VEGF therapy. This recruitment occurs
only after a prolonged schedule of anti-VEGF therapy, when invasion appears.
Furthermore, they accumulate around the peripheral areas of the tumor, and particularly
around invasive nodules. This result suggests a role for this cell population in the
invasive phenotype observed after anti-angiogenic therapy.
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Chapter IV: Increased Ang2 expression is associated with the development of invasion
following anti-VEGF therapy

Rationale and expectations
We have shown an accumulation of Tie2-expressing cells, and Tie2-expressing
monocytes in particular, around the periphery of the tumor following anti-VEGF therapy.
We wanted to further elucidate the status of the Ang-Tie2 pathway following anti-VEGF
therapy, hypothesizing that there was an upregulation of angiopoietin expression leading
to recruitment of Tie2-expressing monocytes to the tumor and potentially modulating
their behavior to aid in the invasive process. At the moment of this study, there were
various reports correlating Ang2 expression with overexpression of MMP2 and invasion
in glioma.78-79 Furthermore, Ang2 has been shown to be expressed in human GBM
surgical samples to a greater extent than in lower grade astrocytomas, particularly in
peripheral areas nad invasive cells.78 Therefore, we expected to find an upregulation of
Ang2 following anti-VEGF therapy and that this had an important role in TEM
recruitment as well as the invasive recurrence of gliomas after treatment.
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Results

Ang2 expression is upregulated after prolonged treatment with VEGFTrap/aflibercept. Using tissue sections from glioma-bearing mice treated with either
control hFc or VEGF-Trap/aflibercept for 3 or 6 weeks, we performed immunostaining
for Ang1 and Ang2 (Figure 3). Ang1 expression, as assessed by immunohistochemical
staining, is below detection levels regardless of treatment status. On the other hand,
Ang2 expression dramatically increases following anti-VEGF therapy. Interestingly, the
increased expression is mainly circumscribed to the periphery of the tumor and invasive
nodules, following the same pattern observed for TEMs. We proceeded to perform
immunofluorescence analysis for quantification purposes (Figure 4). Results obtained
show a significant increase in Ang2 positive cells following anti-VEGF therapy when
compared to control treated tumors or tumors treated for 3 weeks, when invasion does not
occur.
Since VEGF has been associated with invasion in gliomas, we were interested in
evaluating the effect of inhibiting VEGF in the expression of this ligand within the tumor
(Figure 3). Interestingly, we saw an upregulation of VEGF after VEGF/Trap aflibercept.
However, we begin to see this upregulation after only 3 weeks of treatment when
invasion does not occur. This result suggests that increased VEGF expression is not
sufficient to cause the invasive phenotype we observe after prolonged treatment.
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Ang2 upregulation is a common phenomena to all VEGF targeted approaches.
VEGF-Trap/aflibercept is a chimeric antibody composed of the VEGF binding domain of
the VEGFR1 and VEGFR2 attached to the constant portion (Fc) of an IgG for
solubilization.80 Therefore, it works a soluble ligand trap. It is currently in clinical trials
for the treatment of recurrent GBM at MD Anderson Cancer Center. Bevacizumab, on
the other hand, is an anti-VEGF antibody that is currently FDA approved for the
treatment of recurrent GBM. To determine if bevacizumab treatment led to similar
increases in Ang2 as VEGF-Trap/aflibercept, we performed immunostaining for Ang2 in
tissue sections from glioma-bearing mice treated with bevacizumab or control hFc
(Figure 5). Our results show a dramatic increase in Ang2 expression in bevacizumab
treated tumors in a similar pattern as that observed for aflibercept. These data support
that upregulation of Ang2 is a global phenomenon for VEGF targeted therapeutic
approaches regardless of the means used to achieve inhibition.
We then obtained fresh tissue protein lysate from tumors treated with either control
treatment or bevacizumab treatment and performed ELISA to determine Ang2
concentration within the tumor and normal brain from the contralateral hemisphere
(Figure 6).

Our data show an increase in Ang2 expression in tumors treated with

bevacizumab when compared to control treated tumors. This change was not found to be
statistically significant, possibly due to the inherent variability of in vivo models.
Interestingly, Ang2 was barely detectable in normal brain tissue regardless of treatment.
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Temozolomide treatment does not lead to increased Ang2 expression. Temozolomide
(TMZ) is the currently approved chemotherapeutic agent for patients with newly
diagnosed glioblastoma. We wanted to see if upregulation of Ang2 expression was
specific for anti-VEGF approaches or if other therapeutic regimes could also lead to
similar effects. To evaluate this, we performed immunohistochemical staining for Ang2
in tissue sections from glioma-bearing mice treated with either control PBS or TMZ
(Figure 7). Our results show that following TMZ treatment, Ang2 remains localized
mainly in vascular structures and it is not increased as observed for anti-VEGF therapy.
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Characterization of Ang2-expressing cells following anti-VEGF therapy. Given the
varied morphological features of the cells expressing Ang2 after anti-VEGF therapy, we
proceeded to characterize the major contributing cell to the Ang2 pool. For this purpose,
we performed double immunofluorescence for Ang2 in combination with α-SMA as a
marker for pericytes, CD31 as a marker of endothelial cells, Iba1 as a marker of
monocytes or NuMA as a marker of cells from human origin to distinguish glioma cells.
As expected, our results show that pericytes are not a significant source of Ang2,
regardless of treatment. As can be seen in the inset the two dyes do not colocalize
(Figure 8). On the other hand, the vast majority of endothelial cells within the tumor bed
express Ang2 as can be shown by the colocalization of the two dyes in the representative
picture (Figure 9). However, the relative contribution of endothelial cells to Ang2 does
not change significantly with treatment as appreciated in the quantification (lower panel,
Figure 9). Interestingly, monocytes are a significant source of Ang2 (Figure 10), but
upon quantification, their relative contribution decreases with treatment.

Given the

morphological features of the Ang2 expressing cells, we hypothesized that glioma cells
upregulate their expression of Ang2 becoming an important source following antiangiogenic therapy. Since it is very difficult to obtain a cell marker that homogeneously
stains all glioma cells, we took advantage of the fact that we are using a human glioma
cell line on a mouse model. We obtained an antibody that detects only the human form
of the nuclear mitotic apparatus protein (NuMA) and used it to differentiate glioma cells
from all other cells in the tumor micorenvironment. Using this antibody, we performed
double immunofluorescence staining with Ang2 to determine the contribution of glioma
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cells to the Ang2 pool (Figure 11). Taken together, our results show that only within the
glioma compartment is there a significant increase in the relative contribution of Ang2.

43

44

45

46

47

Conclusions

Ang2, a Tie2 ligand, is upregulated following anti-VEGF therapy following the same
spatial pattern as that observed for TEMs. This increase in Ang2 is specific for antiVEGF targeted approaches, since treatment with temozolomide did not lead to similar
changes. Furthermore, characterization of the cells expressing Ang2 showed that the
glioma compartment significantly upregulates expression in response to anti-VEGF
therapy. These data suggest that Ang2 is an important mediator of glioma-acquired
resistance to anti-VEGF therapy and the invasive phenotype observed upon recurrence.
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Chapter V: Ang2 leads to TEM recruitment after anti-VEGF therapy

Rationale and expectations
Ang2 is one of the most studied ligands of Tie2 and it is known to cooperate with VEGF
in the process of angiogenesis.

Given our data on TEM recruitment and Ang2

overexpression after anti-VEGF therapy, we hypothesized that Ang2 is responsible for
the recruitment of TEMs to the tumor following anti-VEGF therapy. We expect Tie2
expressing monocytes to have an enhanced migratory response in the presence of Ang2
than their Tie2 negative counterparts in vitro and in vivo.
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Results

Ang2 induces migration in polarized THP-1 cells, and in particular Tie2 expressing
THP-1 cells. Studying cells of monocytic origin can be very difficult due to their short
duration in culture once isolated from buffy coats. Additionally, TEMs represent 10% or
less of the monocytic population of a normal patient, adding to the difficulty of studying
them. Given these problems, we designed a method to generate TEMs using the THP-1
monocytic leukemia cell line. As described in the materials and methods section, THP-1
cells were M2 polarized and induced to express Tie2 by exposure to hypoxia for 48 hours
in the presence of M2 polarizing cytokines, IL4 and IL13. As controls, cells exposed to
normoxia, normoxia with IL4 and IL13 and hypoxia alone were also evaluated for the
expression of Tie2 (Figure 12). Following 48-72 hours in these conditions, cells were
either used directly and compared to cells placed in normoxia, or sorted for Tie2
expression before migration experiments were done.
After verifying the increase in Tie2 expression following polarizing conditions (Figure
12), migration towards Ang2 of cells exposed to hypoxia with interleukins was tested and
compared to cells placed in normoxia (Figure 13).

Our results show a significant

increase in the number of migrating cells in the cells exposed to hypoxia with IL4 and
IL13 compared to cells placed in normoxia.

To determine whether this increased

migratory response is due to the presence of Tie2 expressing monocytes, we proceeded to
sort THP-1 cells after Tie2 induction and polarizing conditions. Migration of Tie2
negative and Tie2 positive cells towards Ang2 was then evaluated (Figure 14). Our
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results show a significantly higher number of migrating cells in the Tie2 positive THP-1
group than their Tie2 negative counterparts.
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Ang2 leads to TEM recruitment in vivo. To evaluate whether our in vitro findings had
any relevance in the in vivo setting, we proceeded to determine if high Ang2 expression
within the tumor led to increased number of TEMs. For this purpose, tissue sections
from glioma-bearing mice infected with an adenovirus overexpressing Ang2 (AdAng2)
were obtained. To detect and quantify TEMs, double immunofluorescence for Tie2 and
Iba1 was performed (Figure 15). Our results show a dramatic and highly significant
increased number of TEMs in tumors treated with AdAng2 when compared to tumors
treated with AdCMV (empty adenovirus). This confirms that Ang2 is chemoattractant to
TEMs both in vitro and in vivo.
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Conclusions

Ang2 stimulates migration of Tie2 expressing monocytes, both in vitro and in vivo.
These data provide evidence that Ang2 is capable of recruiting Tie2 expressing
monocytes following anti-VEGF therapy. It is worth noting that since our experiments
were performed, another group published similar results in an in vitro setting, which
further validates our data.72
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Chapter VI: Tie2 expressing monocytes promote an environment conducive for
invasion

Rationale and expectations
Tie2 expressing monocytes are a recently discovered subset of circulating monocytes that
express the Tie2 receptor.71 They have been shown to be highly pro-angiogenic and
Ang2 has been shown to further enhance their pro-angiogenic properties.72 There is a
tight interplay between the process of angiogenesis and the process of invasion, with
extensive overlapping in terms of molecules required and associated with each. For
example, MMPs are required to partially degrade the ECM to allow for endothelial
migration during the process of angiogenesis. But, they are also known to promote tumor
invasion and metastasis. Based on the distribution and temporal appearance of TEMs, we
hypothesized they play an important role in the invasive phenotype after anti-VEGF
therapy.

We hypothesized a higher production of pro-invasive molecules, such as

MMPs, in Tie2 positive monocytes when compared with their Tie2 negative counterparts.
Furthermore, we expect Ang2 to further enhance the secretion of said molecules.
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Results

TEMs secrete higher amounts of pro-invasive molecules than their Tie2 negative
counterparts. So far we have shown that anti-VEGF therapy leads to an increase in
Ang2 expression which then leads to recruitment of TEMs. We hypothesized that this
increased representation of TEMs is generating an environment conducive for invasion
through the secretion of pro-invasive molecules that facilitate the process. To test this
hypothesis, we obtained TEMs from peripheral blood of healthy donors as described in
the material and methods section. Figure 16 shows a representative sorting experiment.
Once Tie2 positive and Tie2 negative monocytes were obtained, we cultured them in
serum free media for 24 hours, time after which media was collected and the secretion of
MMP2 and MMP9 was assessed via ELISA (Figure 17). Our results show a highly
significant increased level of expression of both of these molecules by TEMs, when
compared to their Tie2 negative counterparts, supporting the idea that the presence of
TEMs is at least partially responsible for the pattern of recurrence following anti-VEGF
therapy.
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Tie2 expressing cells, potentially TEMs, express MMP9 in vivo. Given the selective
recruitment of TEMs to the periphery of the tumor following anti-VEGF therapy, and
their high expression of MMP9 we wanted to determine whether MMP9 expression was
upregulated within the tumor following anti-VEGF therapy.

To evaluate this we

performed MMP9 immunohistochemistry in tissue sections from glioma-bearing mice
treated with control hFc or VEGF-Trap/aflibercept for 6 weeks. Our results show a
significant increase in the expression of MMP9 following anti-VEGF treatment (Figure
18).
To determine if Tie2 expressing monocytes could be a source of MMP9 in vivo we
performed double immunostaining to detect Tie2 and MMP9 in tissue sections from
glioma-bearing mice treated with bevacizumab (Figure 19).

We evaluated dye

colocalization and were able to detect double positive cells around the periphery of
tumors treated with bevacizumab.

Analysis through confocal microscopy shows

colocalization of the two colors within one cell (lower panel, Figure 19). Morphological
features of these cells support the idea of them being Tie2-expressing monocytes.
However, triple staining adding Iba1 as a monocyte/microglia marker would be helpful to
determine the exact contribution from this cell population to the MMP9 pool.
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Conditioned media from TEMs induces glioma cell invasion in vitro. Given the
significantly higher expression of MMPs observed for TEMs, we hypothesized that
glioma cells would exhibit higher invasion in the presence of conditioned media from
these cells. To test this possibility we initially polarized THP-1 cells in hypoxia with IL4
and IL13 treatment for 48 hours. After 48 hours, Tie2 expression was confirmed through
flow cytometric analysis (Figure 12) and conditioned media was harvested and used for
invasion assays with U87 glioma cells (Figure 20). We observed a significantly higher
number of invading U87 glioma cells when conditioned media from THP-1 cells grown
under hypoxia conditions was used. This increased invasion was further enhanced when
conditioned media from cells also exposed to IL4 and IL13 M2 polarizing cytokines was
used. This further enhancement was also shown to be significant.
To determine if this increased invasion was due to the presence of TEMs, we exposed
THP-1 cells to hypoxia with IL4 and IL13 for 48 hours after which cells were sorted
according to Tie2 expression. After sorting, cells were cultured in serum free media for
24 hours after which conditioned media was harvested and used for invasion assays
(Figure 21). Our results show a significant increase in the number of invading U87
glioma cells and invading GSC20 glioma stem cells in the presence of conditioned media
from TEMs when compared to those in the presence of conditioned media from Tie2
negative monocytes.

65

66

67

Ang2 further enhances the secretion of pro-invasive molecules by TEMs. We have
already shown that Ang2 is at least partially responsible for the increased representation
of TEMs within the tumor after anti-VEGF therapy. We hypothesized that Ang2 is
capable of further enhancing their pro-invasive capabilities. To test this, we obtained Tie2
positive and Tie2 negative monocytes from peripheral blood of healthy donors as
described in the material and methods section. Once cells were obtained, both Tie2+ and
Tie2- monocytes were cultured in serum free media in the presence or absence of Ang2
for 24 hours. At 24 hours, media was collected and gelatinase activity was measured
using the EnzChek Gelatinase/Collagenase Assay (Figure 22). This kit uses a fluorescein
conjugated DQ-gelatin that is so highly labeled that fluorescence is quenched. Gelatinase
activity digests the substrate and produces highly fluorescent fragments. Fluorescence
levels correlate with gelatinase activity. Results obtained show that media obtained from
TEMs has higher gelatinase activity as shown by the significantly higher fluorescence in
the absence of Ang2 when compared to their Tie2 negative counterparts. Furthermore,
our data confirms our hypothesis that Ang2 further enhances this secretion as the
gelatinase activity significantly increased in the presence of Ang2. Interestingly, Ang2
only enhanced the pro-invasive activity in the Tie2 positive population which suggests its
effect is mediated by the Tie2 receptor.
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Conclusions

Through the expression of pro-invasive molecules, such as MMP2 and MMP9, TEMs are
capable of modifying the tumor microenvironment making it one conducive for invasion.
There is an increase in the expression of MMP9 following anti-VEGF therapy and our
data suggests that TEMs are at least partially responsible for this phenomena.
Highlighting the significance of these findings, we were able to show that glioma cells
display enhanced invasive capabilities in the presence of conditioned media from TEMs.
These data demonstrates the importance of TEMs and the Ang-Tie2 pathway in the
invasive recurrence of GBM after anti-VEGF therapy.
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Chapter VII:

Targeting the Ang-Tie2 pathway in combination with anti-VEGF

therapy leads to improved outcomes in syngeneic mouse glioma model.

Rationale and expectations
GBM is a highly aggressive cancer characterized by infiltration into the normal brain.
Recently, bevacizumab was added to the battery of treatments offered to patients with
recurrent GBM and although it has important anti-tumor effects, patients treated with
bevacizumab invariably present with recurrent disease.56 Upon recurrence, these tumors
acquire a highly malignant behavior characterized by enhanced invasion into adjacent
normal brain which renders surgical excision ineffective. Throughout this work we have
provided evidence for the involvement of Ang-Tie2 pathway in the pattern of recurrence
of gliomas following anti-VEGF therapy. We hypothesized that by targeting the AngTie2 pathway in combination with anti-VEGF therapy we will observe improved
outcomes in GBM. We expect to obtain improved survival outcomes as well as a
decrease in the invasive phenotype seen with anti-VEGF monotherapy.
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Results

Targeting VEGFR also leads to an invasive phenotype in a mouse glioma model. To
target the Ang-Tie2 pathway we obtained a GL261 mouse glioma cell line
overexpressing a soluble form of the Tie2 receptor. Upon release of sTie2, it will bind all
the angiopoietins in the media preventing their binding to, and activation of the cellbound Tie2 receptor.

However, given that this is a mouse glioma cell line and

bevacizumab targets only human VEGF, we needed to find a compound that effectively
targets the mouse VEGF pathway. We obtained an antibody named DC101 that targets
mouse VEGFR2 and performed a pilot study to determine if DC101 led to similar
changes as those observed for VEGF-Trap/aflibercept.
We implanted GL261 mouse glioma cells intracranially in C57/BL6 mice and treated
them with either control or DC101 three times a week. Mice were sacrificed when signs
of high tumor burden became apparent and brain was extracted, formalin fixed and
paraffin embedded for morphological studies and protein expression analysis. Upon
histological assessment, GL261 tumors were characterized by a well circumscribed
tumor, with dilated blood vessels and tendency to hemorrhage. No overt necrosis could
be appreciated in either group. Tumors in the control group had a sharp tumor-normal
brain interface and no signs of invasive nodules. On the other hand, tumors treated with
DC101 showed disruption of the interface between tumor and normal brain with fingerlike projections into the normal brain and some areas showing initial detachment from the
main tumor mass, suggesting early stages of invasion (Figure 23).
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DC101 treatment leads to decreased microvascular density. Since targeting the
VEGF-VEGFR pathway disrupts the process of angiogenesis, a way to measure its
effectiveness is quantifying microvascular proliferation within the tumor.

For this

purpose, we performed CD31 staining to label endothelial cells and proceeded to quantify
vascular structures, defined as a cluster of 3 or more endothelial cells having a lumen
(Figure 24). To be considered a discrete vascular structure, the lumen cannot connect
with any other vascular structure within the field. Our results show a decrease in MVD
of more than 50% in tumors treated with DC101 versus control treated tumors. This
provides evidence that DC101 is effectively inhibiting the process of new vessel
formation within the tumor.
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DC101 treatment leads to recruitment of macrophages, Tie2 expressing cells and
TEMs to the periphery of the tumor. We next determined if treatment with DC101 led
to macrophage recruitment, as does bevacizumab and aflibercept. To evaluate this, we
performed Iba1 staining in tissue sections from mice treated with either control treatment
or DC101 (Figure 25). Quantification of Iba1 positive cells revealed a highly significant
increase in macrophage recruitment to the periphery of the tumor. As can be observed in
the image, these cells tend to accumulate right at the interface between tumor and normal
brain.

Treatment with DC101 leads to Tie2 expressing cell accumulation around the
periphery of the tumor and TEM recruitment. We have already shown that antiVEGF therapy with bevacizumab and aflibercept leads to Tie2 expressing cell
accumulation around the periphery of the tumor, and in particular TEM recruitment
around areas of invasion. To determine if DC101 had a similar effect we performed
double immunofluorescence staining for Iba1 and Tie2 (Figure 26). Quantification of
double positive cells shows a significant increase in the fraction of macrophages
expressing the Tie2 receptor following treatment with DC101. Taken together, these data
confirms that DC101 leads to similar changes in the tumor microenvironment as other
human anti-VEGF therapeutic approaches and therefore is a sensible model to study the
effect of macrophage depletion on the responsiveness of tumors to anti-VEGF therapy.
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GL261sTie2 cell line has similar growth kinetics as the control GL261.GFP cell line.
Before proceeding to evaluate whether in the presence of sTie2 gliomas responded better
to anti-VEGF therapy, we wanted to determine if sTie2 expression led to differences in
tumor growth and survival. For this purpose we performed a proliferation assay in vitro
and studied the tumor growth in vivo in C57/BL6 mice (Figure 27). Cells showed no
difference in BrdU incorporation in vitro, demonstrating that there is no significant
difference in their rate of proliferation. Upon implantation, no differences in tumor size
or overall survival were observed with the expression of sTie2.

Upon histological

examination, both GL261.GFP and GL261.sTie2 displayed circumscribed borders with
no invasion towards adjacent normal brain. However, GL261.sTie2 had more extensive
necrotic foci highlighting the importance of an active Ang-Tie2 pathway for the
formation of vascular structures and tissue oxygenation.

Targeting the Ang-Tie2 pathway does not lead to improved survival in a GL261
syngeneic glioma model. One of the most important outcome measures in cancer
treatment is overall survival. Therefore, we were very interested in evaluating whether
targeting the Ang-Tie2 pathway in combination with anti-VEGF therapy led to improved
survival in mice. Mice were implanted with GL261.GFP or GL261.sTie2 and treated
with either control treatment or DC101 three times a week for 4 weeks. Mice were
sacrificed when signs of high tumor burden and overall survival was evaluated for each
group (Figure 28). DC101 treatment alone led to a significant increase in survival when
compared to control therapy. Unfortunately, adding sTie2 to the treatment regimen did
not further increase the overall survival in mice. There could be several reasons for this.
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There is a possibility that targeting the Ang-Tie2 pathway does not lead to improved
survival.

However, because this cell line overexpresses sTie2 from the moment of

implantation and prior to DC101 treatment administration, it is possible that the cells
were able to adapt more quickly to DC101 treatment.
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Targeting the Ang-Tie2 pathwat leads to a significant decrease in the invasive
phenotype after anti-VEGF therapy. One of the main problems arising from antiVEGF therapeutic approaches is the enhancement of invasion observed after therapy.
This renders surgical excision ineffective, which coupled with the highly resistant nature
of GBM leaves patients with little to no therapeutic alternatives. At this point survival is
measured in weeks. Therefore, another important outcome measure in this setting is
preventing the development of invasive feature after anti-angiogenic treatment so that
surgical excision becomes an option in this patient population. We were interested in
evaluating whether targeting the Ang-Tie2 pathway in combination with anti-VEGF
therapy was effective at achieving this goal. Mice were implanted with GL261.GFP or
GL261.sTie2 and treated with either control treatment or DC101 three times a week for 4
weeks. Mice were sacrificed when signs of high tumor burden and brains were extracted,
formalin fixed and paraffin embedded for histological and protein expression analysis.
Histological analysis of tumor sections revealed a striking increase in the number of
invasive nodules when DC101 was administered in GL261.GFP derived tumors. In areas
where no overt invasive nodules could be observed, the tumor-normal brain interface was
disrupted and finger-like projections into the normal brain became to appear. There was
a striking and statistically significant decrease in the number of invasive nodules in
GL261.sTie2 derived tumors treated with DC101 compared to GL261.GFP derived
treated tumors. There were virtually no invasive nodules present and no disruption of the
tumor-normal brain interface (Figure 29).
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Targeting the Ang-Tie2 pathway prevents recruitment of TEMs to the tumor
following anti-VEGF therapy. Our data supports an active role for Ang2 in the
recruitment and modulation of TEMs which then promote an invasive microenvironment
conducive for glioma cell invasion into the normal brain. We wanted to evaluate whether
targeting the angiopoietins effectively prevented the recruitment of TEMs. For this
purpose we obtained tissue sections from GL261.GFP or GL261.sTie2 glioma-bearing
mice treated with either control or DC101 treatment.

Double staining for Iba1, a

monocyte/microglia marker, and Tie2 was performed and double positive cells were
quantified (Figure 30). Our results show a significant decrease in the number of double
positive cells, i.e. TEMs, in GL261.sTie2 derived tumors treated with DC101 when
compared to treated GL261.GFP derived tumors. This result highlights the importance of
available Ang2 for the recruitment of these cells and further supports their role in the
development of invasion following anti-VEGF therapy
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Conclusions

Targeting the Ang-Tie2 pathway in combination with anti-VEGF therapy leads to an
impairment in TEM recruitment and a consequent significant decrease in the invasive
phenotype observed after anti-VEGF therapy.

This has important implications for

patients for GBM. By preventing this enhanced invasive phenotype, we can potentially
render the tumor amenable to surgical excision and this way improve patient survival.
Infiltration of glioma cells into the normal brain is characteristic of GBM and it is
important to understand that curative therapy will require the effective targeting of this
cell population. However, by removing the bulk of the tumor after anti-VEGF therapy
we can significantly improve patient survival, one of the main goals in GBM.
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Chapter VIII: Discussion

GB continues to be a devastating disease, with a median survival of only 15
months despite aggressive chemotherapy.1-2 One of the main features of GBM
contributing to its highly malignant behavior is its infiltrative nature, which makes
complete surgical resection virtually impossible. This, coupled with its highly resistant
nature, makes GB an incredibly difficult cancer to treat.
In 2009, bevacizumab, an anti-VEGF antibody, was FDA approved for the
treatment of recurrent GBM. Treatment with bevacizumab consistently leads to dramatic
radiographic responses and improved progression free survival.47 However, despite its
anti-tumor effects, patients treated with bevacizumab invariably present with recurrent
disease, and upon recurrence the tumor acquires a highly aggressive phenotype
characterized by enhanced invasion and resistance to therapy.52-53,56,79,80 Once patients
present with this stage of disease, there is little to no effective therapy that can be
offered.80 Furthermore, surgical removal is ineffective due to further enhancement of its
already infiltrative behavior.

Therefore, understanding the mechanisms behind the

development of such a malignant disease state will lead to the development of improved
combined therapeutic approaches that can result in better patient outcomes.
The results obtained throughout this project implicate the Ang-Tie2 pathway as a
key player in the recurrence of GBM following anti-VEGF therapy and in particular, the
acquisition of its highly invasive behavior. An accumulation of Tie2 expressing cells
accompanies the development of invasive nodules. Further characterization of these cells
demonstrated them to be TEMs. Shortly after their discovery, TEMs were shown to be
detectable in the blood of healthy donors, comprising less than 10% of circulating
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mononuclear cells in these cases. Furthermore, they comprise the main monocytic
population, other than tumor-associated macrophages, within certain types of solid
tumors. Interestingly, their presence is undetectable in non-neoplastic healthy tissue.73 In
hepatocellular carcinoma (HCC), there is one report correlating the occurrence of TEMs
in the blood of patients with the presence and recurrence of HCC.74 Taken together, these
data suggests that TEMs play a role in cancer development and progression, and supports
the notion that their recruitment following anti-VEGF therapy is an important event
during recurrence. There have been reports where accumulation of tumor associated
macrophages has been linked to anti-angiogenic treatment and correlated with worse
patient survival.82-83 However, the authors did not further characterize this myeloid
population and did not follow up on the association.
MMP9 is shown to be upregulated following anti-VEGF therapy and our data
shows that TEMs have higher secretion of MMP2 and MMP9 than their Tie2 negative
counterparts, suggesting that TEMs are at least partially responsible for the upregulation
of MMP9 following anti-VEGF therapy. Interestingly, the Tie2 receptor has been shown
to be necessary for the secretion of MMP9 by TEMs in vitro81, and we gathered data
showing that Ang2 is capable of further enhancing the secretion of gelatinases by TEMs,
but had no effect in Tie2 negative monocytes. Our data strongly supports that TEMs
have an important role in the invasive phenotype observed after anti-VEGF therapy and
that targeting this population can prove to be beneficial for patients with recurring GBM.
Furthermore, our data highlights the potential benefit of inhibiting the Ang-Tie2 pathway
in the context of anti-VEGF treatment by two distinct mechanisms: 1) TEMs cannot be
recruited to the tumor due to lack of functionally available Ang2 and, 2) Ang2 is not
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available to modulate TEMs that might already be present within the tumor and enhance
their pro-invasive features.
Ang2 has been shown to promote invasion of cancer cells independent of the
tumor microenvironment. Ang2 expression has been correlated with invasion in GBM
and breast cancer surgical samples, and with distant metastasis in the latter.84-85 In
glioma, Ang2 was shown to induce MMP2 expression and increase invasion in vitro.
Furthermore, implantation of U87 glioma cells over-expressing Ang2 led to the
production of invasive tumors in nude mice, a feature largely absent in U87-derived
tumors.86 In this study, authors report on the increased expression of MMP2 in vitro and
in vivo and its contribution to glioma invasion in vitro, but do not characterize the nature
of the infiltrating myeloid cells so their contribution to the invasive features observed
under these conditions remains unexplored. The results obtained in this work provide
evidence that Ang2-mediated TEM recruitment is at least partially responsible for the
invasive features observed after anti-VEGF therapy, and potentially of MMP2
upregulation. However, several mechanisms are likely to be in place and it is possible
that inhibition of the effect of angiopoietins, and in particular Ang2, can also have effects
within the tumor compartment (i.e. cancer cells). It is worth noting that some of the
effects of Ang2 have been shown to be mediated by integrins, particularly α5β1,
suggesting that targeting the ligand would be a better approach than targeting the
receptor.86-87
An important limitation to our approach is that by using sTie2 as a means to
inhibit the Ang-Tie2 pathway, all angiopoietins present within the environment will be
inhibited, which does not allow us to differentiate between the effect of inhibiting each
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one individually. Glioma cells have been shown to express Ang1 which in turn leads to
chemoresistance through upregulation of ABC transporters.88 ABC transporters are not
likely to play a role in resistance to bevacizumab since its mechanism of action does not
require entry into tumor cells. However, it cannot be ruled out that some of the effects
observed in the combination treatment group can be caused by inhibition of Ang1 within
the tumor and tumor vasculature. We were unable to detect Ang1 in glioma tissue
sections, independent of treatment status.

Furthermore, research on TEMs has not

supported a role for Ang1 in their recruitment or modulation, supporting the notion that it
has little to no role in the invasive phenotype observed after anti-VEGF therapy.77
However, this cannot be completely ruled out since we have observed activation of Tie2
with experimentally undetectable levels of Ang1. Furthermore, the Ang1-Tie2 axis has
been shown to enhance adhesion of glioma cells to endothelial cells and induce glioma
cell invasion in vitro.89
Understanding the mechanisms of resistance to anti-VEGF therapy has been the
focus of extensive research since its development. The results depicted throughout this
project suggest a role for the Ang-Tie2 pathway in the modulation of the tumor
microenvironment for the development of invasion as a means to escape VEGF blockade
in gliomas. Several groups, however, have reported on the role of different signaling
pathways in the development of resistance to anti-VEGF therapy in gliomas.

For

example, Carbonell et al. report on the upregulation of integrin β1 following anti-VEGF
therapy in gliomas and provide evidence that targeting integrin β1 potentiates the effects
of bevacizumab in a glioma xenograft and inhibit the development of invasion after
therapy.92 Interestingly, Ang2 has been shown to act through integrins, in particular
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integrin α5β1, and in gliomas it has been shown to enhance MMP2 expression and
invasion through interactions with this integrin.86-87 This suggests a potential interplay
between these two pathways in the recurrent phenotype observed in gliomas. A potential
mechanism of sTie2 at inhibiting invasion after anti-VEGF therapy could be through
inhibition of Ang2-mediated activation of α5β1 integrin.
Another interesting study found an inverse relationship between activation of the
VEGF/VEGFR pathway and c-met phosphorylation and activation in gliomas.93 They
provide evidence that VEGF leads to an inhibition of c-met phosphorylation and
activation and that in the absence of VEGF there is enhanced phosphorylation of this
receptor within glioma cells.

Furthermore, this increased phosphorylation led to

enhanced migration of glioma cells in vitro and enhanced vessel cooption in vivo.
Consequently, they demonstrate enhanced phosphorylation of c-met accompanying
invasion following VEGF blockade, and successfully inhibit the invasive phenotype
observed with anti-VEGF monotherapy with the concurrent inhibition of c-met.
Interestingly, this approach has been shown to be successful at inhibiting invasion and
metastasis in pre-clinical models of other types of solid tumors.94 These studies, along
with others associating a multitude of pathways to anti-VEGF therapy resistance,
highlight the multiplicity of mechanisms used by cancer cells to acquire resistance, and
potentially argue against the use of highly selective therapy (i.e. targeted therapy). More
generalized approaches might be more successful than attempting to target one or several
pathways within the transformed epithelial compartment.

Targeting the tumor

microenvironment, for example through immune modulation, can be such an approach.
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Currently, there are several inhibitors of the Ang-Tie2 pathway either under
development or under pre-clinical or clinical evaluation. Selectively targeting Ang2 as
monotherapy has been shown to be effective at inhibiting tumor growth in several solid
malignancies, including colon carcinoma, renal cell carcinoma, ovarian carcinoma,
pancreatic carcinoma and breast carcinoma.30,90 Added to this, several studies have
explored the value of targeting Ang2 in combination with anti-VEGF therapy and have
shown that the combination therapy has greater anti-tumor effects than either approach
alone.30,91 Currently, there is no preclinical or clinical data assessing the efficacy of
targeting the Ang-Tie2 pathway alone or in combination with bevacizumab in glioma.
We show here that by targeting both, the Ang-Tie2 pathway and the VEGF pathway, we
are able to circumvent the development of invasion in the GL261 syngeneic glioma
model. This has very important implications for GBM patients. As stated above, the
enhanced invasive features observed in recurring tumors after anti-VEGF therapy render
surgical excision ineffective. By effectively preventing the development of enhanced
invasion, we could potentially render the tumors amenable to surgical removal upon
recurrence. It is important to note that GBM is naturally a highly invasive tumor and
complete removal of all tumor cells is virtually impossible at any stage of disease.
Curative therapy will require effectively targeting remaining tumor cells after surgical
removal of the bulk of the tumor. Having said this, being able to improve survival in
patients with GBM is one of the main therapeutic goals and the approach suggested here
has the potential of doing so.
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Chapter IX: Future Directions
Besides upregulation of Ang2, we were also able to see an increase in VEGF
expression after anti-VEGF therapy. Interestingly, we detected a dramatic increase in
binding of VEGF to its receptor within the glioma compartment following bevacizumab
treatment (Figure 31). The hypoxic environment that ensues after anti-VEGF therapy
due to decreased microvascular density is a possible reason for VEGF upregulation in the
context of anti-VEGF therapy.8 Added to this, certain VEGF isoforms bind the
extracellular matrix until protease activity releases them making them available to bind
cell bound receptors.95 The enhanced expression of MMPs observed after anti-VEGF
therapy can lead to release of ECM-bound VEGF upon ECM degradation, which in turn
can explain the enhanced binding to its receptor within the tumor compartment.
Interestingly, VEGF expression has been associated with higher tumor grade in
gliomas.96 Furthermore, it has been associated with increased invasion and metastasis in
several solid malignancies.97-98
The observation of enhanced VEGF binding to its receptor within glioma cells
might seem counterintuitive in the context of bevacizumab treatment, given the fact that
we are administering an anti-VEGF antibody that prevents this same interaction.
However, antibodies (i.e. bevacizumab) generally do not cross an intact blood brain
barrier99 and although the BBB within gliomas is compromised, vessel abnormalities are
thought to impede diffusion of chemotherapeutic drugs to the tumor. Factors such as
high interstitial pressure and chaotic blood flow lead to uneven drug distribution and lack
of drug delivery to some areas of the tumor.100-101 In the presence of bevacizumab, some
of these abnormalities regress, a process called vessel normalization. Although this
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process has been shown to improve delivery of chemotherapeutic drugs, in the context of
GBM vessel normalization is accompanied by restoration of the low permeability
BBB.102 Our observation suggests that regardless of the status of the vascular network
within GBM, bevacizumab is generally not able to reach cancer cells in the brain in
sufficient amounts to cause inhibition outside of the vascular compartment. Given the
tight interplay of the VEGF and the Ang-Tie2 pathway in vessel physiology and
pathology, it would be interesting to explore whether Ang2 can potentiate the effects of
VEGF-VEGFR activation in gliomas or viceversa. Furthermore, in a recent publication
by Niewoehner et al., they report on the development of a modified antibody against βamyloid that has facilitated transport through the BBB via transferrin receptor mediated
transcytocis.103 It would be interesting to apply this technology to anti-VEGF targeted
approaches in GB to improve delivery to the tumor bed.
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Finally, we were interested in understanding the mechanisms through which Ang2
is upregulated following anti-VEGF therapy. Uncovering the molecular players leading
to this phenomenon can lead to the identification of other therapeutic targets to be
combined with anti-VEGF therapy. The Ets family transcription factors Ets-1 and Elf-1
have been reported to act as strong enhancers of endothelial cell Ang-2–promoter
activity.104 In particular, Ets-1 has been shown to strongly induce Ang2 promoter activity
in cervical cancer cells.105 Furthermore, Ets-1 has been associated with malignancy in
gliomas and has been shown to promote invasion and migration in glioma cells.106-107
Therefore, we hypothesized that activation of Ets-1 was responsible for inducing
expression of Ang2 and enhancing the invasive phenotype of gliomas after antiangiogenic treatment. Ras-mediated phosphorylation of Ets1 has been shown to
contribute to its transactivation.108 We obtained an antibody that recognizes the
phosphorylated form of Ets-1 to test our hypothesis. We analyzed tumor cell lysates from
glioma-bearing mice treated with control PBS or bevacizumab for 6 weeks (Figure 32).
We observed a significant increase in phospho-Ets1 levels, suggesting an increase in its
transactivation activity as a response to bevacizumab treatment. Future studies on further
understanding the role of Ets-1 in the regulation of Ang2 within glioma cells, as well as
its role in the invasive recurrence of gliomas after anti-VEGF therapy can shed light on to
the molecular events leading to the highly malignant behavior of gliomas following antiVEGF therapy.
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Chapter X: List of Conclusions
1) Tie2 expressing cells are recruited to the tumor following anti-VEGF therapy in
gliomas.
2) Temozolomide treatment does not lead to recruitment of Tie2 expressing cells.
3) TEMs are recruited to the tumor following anti-VEGF therapy in gliomas.
4) TEMs accumulate in the periphery of the tumor and around areas of invasion
following anti-VEGF therapy.
5) Temozolomide does not lead to recruitment of TEMs.
6) Ang2 is upregulated within the tumor after anti-VEGF therapy in gliomas.
7) Ang2 upregulation after anti-VEGF therapy occurs mainly in the periphery of the
tumor and around areas of invasion.
8) Glioma cells significantly increase their expression of Ang2 after anti-VEGF
therapy.
9) Temozolomide treatment does not lead to Ang2 upregulation.
10) THP-1 cells significantly increase their expression of Tie2 when exposed to
hypoxia in the presence of IL4 and IL13 M2-polarizing cytokines.
11) Ang2 is chemoattractant to TEMs in vitro and in vivo.
12) TEMs secrete higher amounts of MMP2 and MMP9 than their Tie2 negative
counterparts.
13) MMP9 is upregulated in the tumor following anti-VEGF therapy in gliomas.
14) TEMs are a source of MMP9 within the tumor following anti-VEGF therapy.
15) Conditioned media of polarized THP-1 cells induces invasion of glioma cells in
vitro.
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16) Conditioned media from Tie2-expressing THP-1 cells induces invasion of glioma
cells and glioma stem cells in vitro.
17) Targeting the VEGF receptor leads to a similar invasive pattern as that observed
for VEGF-Trap/aflibercept and bevacizumab.
18) Targeting the VEGF receptor leads to a reduction in microvascular density.
19) Targeting the VEGF receptor leads to macrophage recruitment.
20) Accumulation of macrophages following anti-VEGFR treatment occurs mainly in
the peripheral areas.
21) Targeting the VEGF receptor leads to TEM recruitment.
22) Accumulation of TEMs after anti-VEGFR treatment occurs mainly around the
peripheral areas of the tumor.
23) GL261 mouse glioma cells overexpressing soluble Tie2 produce tumors in vivo.
24) GL261.sTie2 and GL261.GFP control cells produce non-invasive tumors.
25) GL261.sTie2 produces more necrotic tumors than GL261.GFP control cells.
26) Targeting the Ang-Tie2 pathway using a sTie2 in combination with anti-VEGF
therapy does not lead to improved survival.
27) Targeting the Ang-Tie2 pathway using sTie2 in combination with anti-VEGF
therapy leads to decreased invasion.
28) Targeting the Ang-Tie2 pathway using sTie2 in combination with anti-VEGF
therapy prevents recruitment of TEMs to the tumor.
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Figure 33. Role of the Ang-Tie2
Tie2 pathway in the invasive recurrence of glioblastoma following anti-VEGF
therapy. An inititally circumscribed tumor is exposed to an agent targeting the VEGF pathway. This leads to
vessel regression and hypoxia, causing an increase in the expression of VEGF. Through mechanisms not yet
identified, Ang2 is upregulated within glioma cells. Ang2 upregulation leads to recruitment of Tie2-expressing
Tie2
cells, and TEMs in particular. TEMs secrete high amoun
amounts of pro-invasive
invasive molecules such as MMPs, and this
activity is further enhanced by Ang2. This leads to degradation of the extracellular matrix providing a pathway
for tumor cell migration and invasion into adjacent structures. The driving forces behind glioma
g
cell migration
and invasion remain obscure.
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